IN THE CLAIMS

14. (Currently amended) A method of preparing a plasma-protein-containing medicament using as a starting material one selected from the group consisting of citrated plasma and a citrate-containing plasma fraction, wherein (I) said medicament is substantially free from undesired metals selected from the group consisting of aluminum, cadmium, zinc, lead and iron, and (II) said medicament does not take up any undesired metals when stored in metal-containing containers, wherein said method comprises

~~exchanging~~ replacing citrate and ~~optionally~~ , if present, citrate-bound metals in a plasma-protein-containing solution for one selected from the group consisting of a water-soluble monocarboxylate, a water-soluble dicarboxylate, a monocarboxylic acid and a dicarboxylic acid, wherein the ~~exchanging~~ replacing occurs under non-precipitating conditions,

recovering at least one plasma protein, and

finishing said medicament.

15. (Previously presented) The method as set forth in claim 14, wherein said at least one plasma protein recovered is selected from the group consisting of the factors of coagulation, factors of fibrinolysis, immunoglobulins, glycoproteins and albumin.

16. (Previously presented) The method as set forth in claim 14, wherein monocarboxylate, dicarboxylate, monocarboxylic acidor dicarboxylic acid has 2 to 20 carbon atoms.

17. (Currently amended) The method as set forth in claim 14, wherein said ~~exchanging~~ replacing of said citrate and ~~optionally of~~ , if present, said citrate-bound metals is performed using ~~a t~~ at least one substance selected from the group consisting of a caprylate and a tartrate.

18. (Currently amended) The method as set forth in claim 14, wherein said ~~exchanging~~ replacing of said citrate and ~~optionally of~~ , if present, said citrate-bound metals is performed using a monocarboxylic or dicarboxylic acid having 2 to 4 carbon atoms.

19. (Canceled).

20. (Currently amended) The method as set forth in claim 14, wherein said ~~exchanging~~ replacing of said citrate and ~~optionally of~~ , if present, said citrate-bound metals is performed during one of a diafiltration, ultrafiltration, gel permeation chromatography and a chromatographic separation method.

21. (Currently amended) The method as set forth in claim 14, further comprising subjecting said plasma-protein-containing solution to at least

one of a purification and a concentration procedure before said ~~exchanging~~ replacing of said citrate and ~~optionally of~~ , if present, said citrate-bound metals.

22. (Previously presented) The method as set forth in claim 14, further comprising subjecting said plasma-protein-containing solution to a treatment for virus inactivation.

23. (Currently amended) The method as set forth in claim 22, wherein said treatment for virus inactivation is performed before said ~~exchanging~~ replacing of said citrate and ~~optionally of~~ , if present, said citrate-bound metals.

24. (Currently amended) The method as set forth in claim 22, wherein said treatment for virus inactivation is performed after said ~~exchanging~~ replacing of said citrate and ~~optionally of~~ , if present, said citrate-bound metals.

25. (Currently amended) The method as set forth in claim 22, wherein said treatment for virus inactivation is performed before and after said ~~exchanging~~ replacing of said citrate and ~~optionally of~~ , if present, said citrate-bound metals.

26. (Previously presented) The method as set forth in claim 22, wherein said treatment for virus-inactivation is a heat-treatment.

27. (Previously presented) The method as set forth in claim 22, wherein said treatment for virus inactivation is performed immediately after said recovering of at least one plasma protein in the presence of the monocarboxylate or dicarboxylate.

28. (Previously presented) The method as set forth in claim 14, wherein the finishing of said medicament is performed using only citrate-free components.

29. (Currently amended) The method as set forth in claim 14, wherein said ~~exchanging~~ replacing of said citrate and ~~optionally of~~ , if present, said citrate-bound metals is performed in the presence of sodium chloride.

30. (Previously presented) The method as set forth in claim 29, wherein said sodium chloride is an at least 4% by weight sodium chloride solution.

31. (Currently amended) A plasma-protein-containing medicament ~~using as a starting material~~ made from one selected from the group consisting of citrate plasma and a citrate-containing plasma fraction, wherein the medicament is (I) substantially free from undesired metals selected from the group consisting of aluminum, cadmium, zinc, lead and iron, and (II) said medicament does not take up any undesired metals when stored in metal-containing containers, wherein the medicament is obtained by

~~exchanging~~ replacing citrate and ~~optionally of~~ , if present, citrate-bound metals in a plasma-protein-containing solution for one selected from the group consisting of a water-soluble monocarboxylate, a water-soluble dicarboxylate, a water-soluble monocarboxylic acid and a water-soluble dicarboxylic acid, wherein the ~~exchanging~~ replacing occurs under non-precipitating conditions,

recovering at least one plasma protein, and

finishing said medicament, wherein said medicament has a content of undesired metals of less than 100 ~~µg/1~~ µg/l.

32. (Canceled).

33. (Previously presented) The plasma-protein-containing medicament as set forth in claim 31, wherein said content of undesired metals is less that 10 µg/l.

34. (Currently amended) The plasma-protein-containing medicament as set forth in claim 31, wherein said content of undesired metals is less than 200 ~~ng/1~~ ng/l.

35. (Previously presented) The method according to claim 14, wherein the medicament has a content of undesired metals of less than 100 µg/l.

36. (Curently amended) The method according to claim 35, wherein the medicament has a content of undesired metals of less than 10 ~~µg/1~~ µg/l.

37. (Previously presented) The method according to claim 36, wherein the medicament has a content of undesired metals of less than 200 ng/l.